FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3177804952> ?p ?o ?g. }

• W3177804952 endingPage "1261" @default.
• W3177804952 startingPage "1250" @default.
• W3177804952 abstract "Most data regarding the use of disease-modifying therapies (DMTs) in multiple sclerosis (MS) comes from clinical series or regional databases that have a risk of recruitment bias. French health administrative data offers the significant advantage of being extensive in regards to both MS population coverage and DMT prescriptions.To describe patterns of DMTs usage at the level of the entire French population of MS patients from 2010 to 2015.MS patients were identified during a 6-year study period via the French national health data system (covering 97% of the general population) and characteristics of patients who received at least one treatment were compared to those that never received treatment over the indicated period. A state sequence analysis was performed to study in a longitudinal way MS patients who started DMTs in 2010 and then to classify them into groups of similar therapeutic patterns. DMTs were categorized into first-line, second-line and off-label use, and included untreated periods for at least six months. Groups that were obtained were described and compared using a multinomial logistic regression.A total of 112,415 patients with MS were identified, of whom 54.0% received at least one DMT over the 6 years. The probability of being treated significantly decreased with age. Comorbidities and physical limitations appeared to be more frequent in not treated patients than in treated patients. Significant differences were also found between the two groups regarding the use of healthcare services (hospitalizations and visits to general practitioner, neurologist and nurse). Based on the 6-year therapeutic sequences, a four-cluster typology was obtained on the 4,474 patients who started a DMT in 2010. The first group which consisted of more than half of the patients (57.0%) mainly used first-line DMTs. The second group (13.1%) represented patients with second-line DMTs whereas the third group (7.3%) was comprised of off-label users and the last group (22.6%) was composed of MS patients who received no or minimal treatments. Classification into one of these groups was associated with patient's age, long-term disease status, pregnancy occurrence, estimated level of disability, levels of care (visits to a neurologist, nurse and/or physiotherapist and hospital/rehabilitation stays) and occurrence of death.The exhaustive population-based dataset from the French national health data system gave the opportunity to provide a detailed description regarding the use of DMTs for MS at national level. The innovative method of state sequence analysis allowed obtaining four homogeneous groups of patients among thousands of longitudinal therapeutic sequences. The predominant place of first-line treatments was confirmed even if the type of first-line treatments has probably changed since 2015." @default.
• W3177804952 created "2021-07-19" @default.
• W3177804952 creator A5002642951 @default.
• W3177804952 creator A5032354374 @default.
• W3177804952 creator A5049423140 @default.
• W3177804952 creator A5064097430 @default.
• W3177804952 creator A5083907860 @default.
• W3177804952 date "2021-12-01" @default.
• W3177804952 modified "2023-10-13" @default.
• W3177804952 title "Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study" @default.
• W3177804952 cites W1928823211 @default.
• W3177804952 cites W1948664808 @default.
• W3177804952 cites W1984920393 @default.
• W3177804952 cites W2000445173 @default.
• W3177804952 cites W2022468610 @default.
• W3177804952 cites W2028879896 @default.
• W3177804952 cites W2045823794 @default.
• W3177804952 cites W2114741326 @default.
• W3177804952 cites W2199914463 @default.
• W3177804952 cites W2580622791 @default.
• W3177804952 cites W2614460177 @default.
• W3177804952 cites W2741789802 @default.
• W3177804952 cites W2800173245 @default.
• W3177804952 cites W2804968317 @default.
• W3177804952 cites W2904039091 @default.
• W3177804952 cites W2995944114 @default.
• W3177804952 cites W3087170161 @default.
• W3177804952 doi "https://doi.org/10.1016/j.neurol.2021.04.006" @default.
• W3177804952 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34253346" @default.
• W3177804952 hasPublicationYear "2021" @default.
• W3177804952 type Work @default.
• W3177804952 sameAs 3177804952 @default.
• W3177804952 citedByCount "6" @default.
• W3177804952 countsByYear W31778049522021 @default.
• W3177804952 countsByYear W31778049522022 @default.
• W3177804952 countsByYear W31778049522023 @default.
• W3177804952 crossrefType "journal-article" @default.
• W3177804952 hasAuthorship W3177804952A5002642951 @default.
• W3177804952 hasAuthorship W3177804952A5032354374 @default.
• W3177804952 hasAuthorship W3177804952A5049423140 @default.
• W3177804952 hasAuthorship W3177804952A5064097430 @default.
• W3177804952 hasAuthorship W3177804952A5083907860 @default.
• W3177804952 hasBestOaLocation W31778049521 @default.
• W3177804952 hasConcept C104863432 @default.
• W3177804952 hasConcept C118552586 @default.
• W3177804952 hasConcept C126322002 @default.
• W3177804952 hasConcept C151956035 @default.
• W3177804952 hasConcept C187212893 @default.
• W3177804952 hasConcept C2426938 @default.
• W3177804952 hasConcept C2779134260 @default.
• W3177804952 hasConcept C2780640218 @default.
• W3177804952 hasConcept C2908647359 @default.
• W3177804952 hasConcept C512399662 @default.
• W3177804952 hasConcept C71924100 @default.
• W3177804952 hasConcept C98274493 @default.
• W3177804952 hasConcept C99454951 @default.
• W3177804952 hasConceptScore W3177804952C104863432 @default.
• W3177804952 hasConceptScore W3177804952C118552586 @default.
• W3177804952 hasConceptScore W3177804952C126322002 @default.
• W3177804952 hasConceptScore W3177804952C151956035 @default.
• W3177804952 hasConceptScore W3177804952C187212893 @default.
• W3177804952 hasConceptScore W3177804952C2426938 @default.
• W3177804952 hasConceptScore W3177804952C2779134260 @default.
• W3177804952 hasConceptScore W3177804952C2780640218 @default.
• W3177804952 hasConceptScore W3177804952C2908647359 @default.
• W3177804952 hasConceptScore W3177804952C512399662 @default.
• W3177804952 hasConceptScore W3177804952C71924100 @default.
• W3177804952 hasConceptScore W3177804952C98274493 @default.
• W3177804952 hasConceptScore W3177804952C99454951 @default.
• W3177804952 hasIssue "10" @default.
• W3177804952 hasLocation W31778049521 @default.
• W3177804952 hasLocation W31778049522 @default.
• W3177804952 hasLocation W31778049523 @default.
• W3177804952 hasOpenAccess W3177804952 @default.
• W3177804952 hasPrimaryLocation W31778049521 @default.
• W3177804952 hasRelatedWork W1565412750 @default.
• W3177804952 hasRelatedWork W2109927828 @default.
• W3177804952 hasRelatedWork W2159453684 @default.
• W3177804952 hasRelatedWork W2180948368 @default.
• W3177804952 hasRelatedWork W2498291051 @default.
• W3177804952 hasRelatedWork W2552583352 @default.
• W3177804952 hasRelatedWork W2617222556 @default.
• W3177804952 hasRelatedWork W2802859181 @default.
• W3177804952 hasRelatedWork W2895819372 @default.
• W3177804952 hasRelatedWork W4304689155 @default.
• W3177804952 hasVolume "177" @default.
• W3177804952 isParatext "false" @default.
• W3177804952 isRetracted "false" @default.
• W3177804952 magId "3177804952" @default.
• W3177804952 workType "article" @default.